Effects of Sevelamer Carbonate on Heart Health in Kidney Disease
Author Information
Author(s): Chue Colin D, Townend Jonathan N, Steeds Richard P, Ferro Charles J
Primary Institution: University Hospitals Birmingham NHS Foundation Trust
Hypothesis
Phosphate binding with sevelamer carbonate will reduce left ventricular mass, improve indices of left ventricular systolic and diastolic function, and reduce arterial and cardiac stiffness in patients with stage 3 CKD.
Conclusion
The study aims to determine if sevelamer carbonate can improve heart function and reduce stiffness in patients with chronic kidney disease.
Supporting Evidence
- Serum phosphate is linked to heart problems in kidney disease.
- Sevelamer carbonate is a non-calcium phosphate binder.
- Previous studies suggest sevelamer may help reduce heart risks.
Takeaway
This study is trying to find out if a medicine called sevelamer can help people's hearts work better when they have kidney problems.
Methodology
A single-centre, prospective, randomised, double-blind, placebo-controlled trial with 120 subjects receiving either sevelamer carbonate or placebo over 40 weeks.
Potential Biases
Potential bias in participant selection and reporting of outcomes due to the single-centre design.
Limitations
The study is limited to a single centre and may not be generalizable to all populations.
Participant Demographics
Adults aged 18-80 years with stage 3 chronic kidney disease.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website